RESUMO
Hedychium coronarium Koen., commonly known as ginger lily, is considered an endemic medicinal plant. In the present study, the antidiabetic action of its rhizomes was investigated by α-amylase and α-glucosidase inhibition assay, and the active compounds were identified through bioactivity guided isolation technique. Among the six different extracts, the EA extract has shown highest inhibition, and the subfractions from active EA extract were separated by silica gel column chromatography. The subfraction showing highest inhibition was investigated for its chemical composition by high-resolution liquid chromatography-mass spectroscopy (HRLC-MS/MS). The fatty acids such as suberic acid and terpenes such as triparanol, ginkgolide C, and swietenine were found to be the major compounds in the subfractions. The present work revealed that H. coronarium rhizome extract and its active constituent could be used as a natural inhibitor of these two carbohydrate-metabolizing enzymes and may play a key role in the management of diabetes.
Assuntos
Inibidores de Glicosídeo Hidrolases/farmacologia , Hipoglicemiantes/farmacologia , Extratos Vegetais/farmacologia , Zingiberaceae/química , alfa-Amilases/antagonistas & inibidores , alfa-Glucosidases/metabolismo , Caprilatos/análise , Caprilatos/farmacologia , Caprilatos/uso terapêutico , Diabetes Mellitus , Ácidos Dicarboxílicos/análise , Ácidos Dicarboxílicos/farmacologia , Ácidos Dicarboxílicos/uso terapêutico , Ginkgolídeos/análise , Ginkgolídeos/farmacologia , Ginkgolídeos/uso terapêutico , Inibidores de Glicosídeo Hidrolases/análise , Hipoglicemiantes/análise , Lactonas/análise , Lactonas/farmacologia , Lactonas/uso terapêutico , Limoninas/análise , Limoninas/farmacologia , Limoninas/uso terapêutico , Fitoterapia , Extratos Vegetais/química , Rizoma/química , Terpenos/análise , Terpenos/farmacologia , Terpenos/uso terapêutico , Triparanol/análise , Triparanol/farmacologia , Triparanol/uso terapêuticoAssuntos
Anticolesterolemiantes/uso terapêutico , Aterosclerose/tratamento farmacológico , Colesterol/metabolismo , Anticolesterolemiantes/farmacologia , Aterosclerose/etiologia , Medicina Clínica/história , História do Século XX , Humanos , Metabolismo dos Lipídeos , Triparanol/farmacologia , Triparanol/uso terapêuticoRESUMO
Despite the improved contemporary multidisciplinary regimens treating cancer, majority of cancer patients still suffer from adverse effects and relapse, therefore posing a significant challenge to uncover more efficacious molecular therapeutics targeting signaling pathways central to tumorigenesis. Here, our study have demonstrated that Triparanol, a cholesterol synthesis inhibitor, can block proliferation and induce apoptosis in multiple human cancer cells including lung, breast, liver, pancreatic, prostate cancer and melanoma cells, and growth inhibition can be rescued by exogenous addition of cholesterol. Remarkably, we have proved Triparanol can significantly repress Hedgehog pathway signaling in these human cancer cells. Furthermore, study in a mouse xenograft model of human lung cancer has validated that Triparanol can impede tumor growth in vivo. We have therefore uncovered Triparanol as potential new cancer therapeutic in treating multiple types of human cancers with deregulated Hedgehog signaling.